nach oben

Reactions Weekly

Erschienen in:

01.11.2018 | Case report

Erlotinib

Skin toxicities: case report

Erschienen in: Reactions Weekly | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Excerpt

In a retrospective multi-centre study, a patient [age and sex not stated] was described, who developed skin toxicities during treatment with erlotinib for advanced non-small cell lung cancer (NSCLC). The patient, who had advanced NSCLC, started receiving treatment with erlotinib 150mg once a day [route not stated]. However, the patient developed skin toxicities [outcome not stated]. Therefore, the patient's dose of erlotinib was reduced to 100mg once a day. …

Berzinec P, et al. Advanced NSCLC Treated with Gefitinib or Erlotinib for Five Years or Longer - Retrospective Slovakian Study. Journal of Thoracic Oncology 13 (Suppl.): S980 abstr. 13.11, No. 10, Oct 2018. Available from: URL: http://doi.org/10.1016/j.jtho.2018.08.1851 [abstract] - Slovakia

Titel: Erlotinib
Skin toxicities: case report
Publikationsdatum: 01.11.2018
Verlag: Springer International Publishing
Erschienen in: Reactions Weekly / Ausgabe 1/2018
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-018-54414-4

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Erlotinib

Skin toxicities: case report

Excerpt

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2018

Paracetamol

Cetuximab/panitumumab

Docetaxel

Nivolumab

Methylphenidate

Infliximab